Today I am proud to announce the appointment of two new members to the BrightInsight Advisory Council: Tamara Elias, M.D. and Scott Huennekens will bring deep and complementary experience to this group of industry experts who work with BrightInsight leadership to advance the company’s vision to transform patient outcomes globally through the power of digital technology.
We are thrilled to have Dr. Tamara Elias and Scott Huennekens join our Advisory Council, providing insights based on their decades of leadership in digital innovation and adoption in life sciences. Our team and clients will benefit from their counsel as we continue growing internationally and expanding our portfolio of digital health solutions.
Tamara and Scott are joining the Advisory Council as BrightInsight continues to solidify our position as the de facto digital health platform for biopharma and medtech. So far in 2022 we’ve announced our partnership with Sanofi, which joins a list of customers that includes CSL Behring, Roche, Novo Nordisk and more. And we launched our BrightInsight Connected Diagnostics Platform for in vitro diagnostics and our digital Disease Management Solution.
Tamara has been avidly involved with healthcare for over 20 years across a spectrum of diverse experiences, beginning with medical school, extending into surgical residency, followed by healthcare strategic consulting, private equity investing, corporate strategy and business development, and product innovation, inclusive of board member positions.
Currently, as Senior Vice President, Strategy and Business Incubation at Nuance Communications, a Microsoft Company, she orchestrates complex processes and initiatives to understand how these two companies’ unique assets can be used to advance workflows and improve diagnoses across the healthcare ecosystem. In her prior role at Merck she was Vice President of Global Partnerships & Innovation, realizing “around the pill” innovations for their stakeholders. Prior to Merck, she served as Aetna’s Vice President of Clinical Product Development, as well as Vice President, Strategy and Business Development at Becton Dickinson. Earlier in her career she was a partner at Essex Woodlands Health Partners, a McKinsey manager, and a general surgeon. She currently sits on the boards of Avinger, REVA Medical LLC, and BehaVR.
“Digital touches every area of healthcare, including biopharma, which traditionally does not hold expertise in regulated platforms,” she said. “BrightInsight plays a key role in meeting biopharma companies where they are to drive value and differentiation for their therapies. I’m excited to join the BrightInsight Advisory Council and work with the team to advance the life sciences industry adoption of digital.”
Scott is a seasoned medtech CEO, chairperson, board member, entrepreneur and investor, having been in one of those roles for more than 20 startup, growth and public companies with market valuations that have totaled over $20B. He currently serves as Executive Chairperson of Hyperfine, Chairperson of Acutus Medical, Chairperson of Envista, board member of NuVasive, and Executive Chairperson and Investor of Wondr Medical. Over 20 million patients have benefited from the therapies and diagnostics produced by the companies Scott has been involved with.
“As the medtech industry advances, it’s all about digital with its guiding principle being connectivity that enables collecting and activating data,” he said. “It is important for medtech to share data across the continuum of care—driving collaboration, enabling better care and reducing costs. To achieve these goals, a regulated digital health platform is needed to ensure medtech and diagnostic companies comply with quality, security, regulatory and privacy requirements. I’m pleased to join the BrightInsight Advisory Council, and to work with the team to continue to advance and customize their offerings for innovative medtech companies.”
Tamara and Scott join some of the world’s most accomplished healthcare, technology and business thought leaders on the BrightInsight Advisory Council, including Mark T. Bertolini, Karl Hick, Donald Jones, Jeffrey Leiden, M.D., Ph.D., Diana McKenzie, Stephen Oesterle, Kim Powell, Brent Saunders, Meinhard F. Schmidt, Jagjot (JJ) Singh, Bradley Stock, Hemant Taneja and Elisabethann Wright.